Impact of Preoperative CA 15-3 Levels in Operable Breast Cancer. Comparison with Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA)

Iaffaioli, Rosario Vincenzo; Caponigro, Francesco; Esposito, Gennaro; Pagliarulo, Caterina; Deplacido, S; Ungaro, Biagio; Bazzicalupo, L.; Frasci, G.; Bianco, A. R.

doi:10.1177/172460089100600104

Cited by 10 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results therefore confirm previously reported results [7][8][9][10][11][12][13][14][15][16] concerning the prognostic value of initial CA 15-3 concentration in patients without metastases at diagnosis. Cox model identified initial CA 15-3 concentration as an independent prognostic factor, the most important after lymph node invasion.…”

supporting

confidence: 83%

Value of CA 15-3 determination in the initial management of breast cancer patients

Chourin¹,

Georgescu²,

Gray³

et al. 2009

Annals of Oncology

View full text Add to dashboard Cite

supporting

confidence: 83%

Value of CA 15-3 determination in the initial management of breast cancer patients

Chourin¹,

Georgescu²,

Gray³

et al. 2009

Annals of Oncology

View full text Add to dashboard Cite

“…Our study showed that patients presenting CA15-3 levels over 40U/ml (cut-off) have both worse disease free interval (DFS) and overall survival (OS) compared to those with concentrations <40U/ml. This is supported by Iaffaioli and co-workers that reported that patients with high preoperative levels of CA 15-3 (>30 U/ml) have shorter disease-free interval than patients with lower levels [28]. The present study also demonstrated that preoperative CA 15-3 levels are significantly associated with early recurrences of the disease, thus adding useful information to prognosis especially in lymph node-positive patients.…”

Section: Discussionsupporting

confidence: 87%

“…In particular, these authors reported that the median value of CA 15-3 (43kU/l) in 26 patients with stage IV disease (86% patients with bone metastasis) was significantly higher than the median for 97 patients classified as stage I or II (17 kU/I) [28]. Our study showed that patients presenting CA15-3 levels over 40U/ml (cut-off) have both worse disease free interval (DFS) and overall survival (OS) compared to those with concentrations <40U/ml.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Clinical Usefulness of Cancer Antigen 15-3 in Breast Cancer Patients Before and After Surgery

Daniele

Divella

Trerotoli

et al. 2013

TOBCANJ

View full text Add to dashboard Cite

Abstract:Background: Cancer Antigen 15-3 (CA 15-3) is a tumor-associated antigen used as serum marker for breast cancer surveillance in patients and for monitoring the response to treatment. Aim of this study was to retrospectively evaluate CA 15-3 as a prognostic factor in early detection of breast cancer relapse as well as to analyze the statistical correlation between CA 15-3 levels and clinical-pathological parameters including staging, grading, estrogen and progesterone receptors.Methods: Sera of 726 women with breast carcinoma obtained preoperatively and postoperatively were assayed for CA 15-3 by chemoluminescent immunometric assay.Results: We found that the mean serum CA 15-3 levels in patients before surgery were significantly higher (36.59 U/ml) compared with those of CA 15-3 after surgery (27.11 U/ml). We also found that elevated preoperative serum levels of CA 15-3 were significantly correlated with the presence of metastatic disease. In particular, among 305/700 patients (43,6%) that displayed over cut-off (>40U/ml) preoperative levels of CA 15-3, 94 patients (30,8%) developed advanced disease (metastases to distant sites). By contrast, in a subgroup of 395/700 patients (56.4%) with CA 15.3 serum levels < 40U/ml, only 32/305 patients (8%) showed signs of advanced disease during follow-up. Cox regression analysis revealed that only the presence of metastasis and the increased serum levels of CA 15-3 after surgery are significant risk factors for relapse of disease.Conclusion: Elevated preoperative concentrations of CA 15-3 may be a useful predictive factor for cancer progression in postoperative patients.

show abstract

“…At least 10 published studies involving Ͼ4000 patients have addressed the relationship between preoperative concentrations of CA 15-3 and patient outcome (Table 3) (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). Although a range of cutoff points were used (25-40 kilounits/L), all of the identified studies apart from one concluded that high concentrations of the marker at initial presentation predicted adverse patient outcome.…”

Section: Determining Prognosismentioning

confidence: 99%

Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?

2006

View full text Add to dashboard Cite

Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. Methods: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. Results: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers is of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of ϳ2-9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria. Conclusions: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.

show abstract

Impact of Preoperative CA 15-3 Levels in Operable Breast Cancer. Comparison with Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA)

Cited by 10 publications

References 12 publications

Value of CA 15-3 determination in the initial management of breast cancer patients

Value of CA 15-3 determination in the initial management of breast cancer patients

Clinical Usefulness of Cancer Antigen 15-3 in Breast Cancer Patients Before and After Surgery

Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?

Contact Info

Product

Resources

About